Our latest episode of #WhatsWithRWE is now live! 🎉 In this episode, we’re thrilled to welcome Tim Errington, Senior Director of Research at @OSFramework! Join Tim and Lester as they dive into the ins and outs of replicating scientific studies. #researchyoutu.be/JrPlkQhwluM
✨New episode of #WhatsWithRWE! We're honored to be joined by @clopezcorrea, CSO of @genomecanada. She shares her path into the fascinating world of genomics, and how this insight guided her cancer treatment when she was diagnosed with breast cancer. youtu.be/abEuP4rDU_E
🎙️Chere from @ArdeaOutcomes explains how goal attainment scaling gathers data that reflects what truly matters to patients, and how this approach unveils a more comprehensive depiction of a drug’s effects during #clinicaltrials. #clinicalresearchyoutu.be/jR2ldv4ISd0
🚨 New release of #WhatsWithRWE! We spoke with Chere Chapman, CEO of @ArdeaOutcomes, a Canadian CRO focusing on goal attainment scaling (GAS) in #clinicaltrials. Watch the short video below (5 min) as Chere dives into the genesis of the organization.
youtu.be/TxZqjDB8lHU
Time to unveil the results of last week's poll! 📊
How long does it take for a new #drug in Canada to go from @GovCanHealth authorization to reimbursement?
The answer is on average 632 days!
In a comparison of 20 #OECD countries, Canada ranked 19th. #LastMileforMedicines
Our colleague @G4DNA is representing us at the Canadian Lung Cancer Conference in Vancouver today! It's a perfect opportunity to share a clip of our conversation with Dr Natasha Leighl, an expert in #lungcancer and #liquidbiopsies. #WWRWE#CLCCyoutu.be/_Nx0MgY1ZpY
The approval of new #cancer therapies usually relies on #clinicaltrials. But how do we know how these therapies affect patients in the real world? Dr Natasha Leighl from @UHN highlights how #RWE studies can fill this gap by collecting real-world data #RWDyoutu.be/pLBnnAD0tRQ
We're proud to announce the #publication of our #research featured in the @IJMS_MDPI. This paper represents the extensive efforts of our team to understand the safety and efficacy of regorafenib as a second-line treatment for metastatic #colorectalcancer.
mdpi.com/2606708
We were thrilled to present our PMT Databank with esteemed hematologist-oncologists at the Montreal Jewish General Hospital last month. We are excited to announce that we are working to add hematological cancer patient data to our already robust databank. #RWE#RWD
When faced with a cancer diagnosis, many patients turn to "Dr. Google." @BreastCancerCDN has developed a better option that aims to deliver highly pertinent and comprehensive results for those seeking answers following a breast cancer diagnosis.
torontosun.com/news/national…